$2.75
0.40[17.02%]
Last update: 7:37AM Get Real Time Here
Indaptus Therapeutics
(NASDAQ:INDP)Indaptus Therapeutics Stock (NASDAQ:INDP), Analyst Ratings, Price Targets, Predictions
Indaptus Therapeutics Inc has a consensus price target of $14, established from looking at the 11 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co. on April 15, 2024, September 20, 2023, and August 15, 2023. With an average price target of $12 between HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co., there's an implied 336.36% upside for Indaptus Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Maxim Group
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Indaptus Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/15/2024 | INDP | Buy Now | Indaptus Therapeutics | $2.75 | 336.36% | HC Wainwright & Co. | Raghuram Selvaraju | → $12 | Reiterates | Buy → Buy | Get Alert |
| 09/20/2023 | INDP | Buy Now | Indaptus Therapeutics | $2.75 | 336.36% | HC Wainwright & Co. | Raghuram Selvaraju | → $12 | Reiterates | Buy → Buy | Get Alert |
| 08/15/2023 | INDP | Buy Now | Indaptus Therapeutics | $2.75 | 336.36% | HC Wainwright & Co. | Raghuram Selvaraju | → $12 | Reiterates | Buy → Buy | Get Alert |
| 08/11/2023 | INDP | Buy Now | Indaptus Therapeutics | $2.75 | 336.36% | HC Wainwright & Co. | Raghuram Selvaraju | → $12 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2023 | INDP | Buy Now | Indaptus Therapeutics | $2.75 | 336.36% | HC Wainwright & Co. | Raghuram Selvaraju | → $12 | Reiterates | Buy → Buy | Get Alert |
| 05/04/2023 | INDP | Buy Now | Indaptus Therapeutics | $2.75 | 336.36% | HC Wainwright & Co. | Raghuram Selvaraju | → $12 | Reiterates | → Buy | Get Alert |
| 03/20/2023 | INDP | Buy Now | Indaptus Therapeutics | $2.75 | 336.36% | HC Wainwright & Co. | Raghuram Selvaraju | $15 → $12 | Maintains | Buy | Get Alert |
| 03/08/2023 | INDP | Buy Now | Indaptus Therapeutics | $2.75 | 445.45% | HC Wainwright & Co. | Raghuram Selvaraju | → $15 | Reiterates | → Overweight | Get Alert |
| 02/08/2023 | INDP | Buy Now | Indaptus Therapeutics | $2.75 | 445.45% | HC Wainwright & Co. | Raghuram Selvaraju | → $15 | Reiterates | → Buy | Get Alert |
| 01/31/2022 | INDP | Buy Now | Indaptus Therapeutics | $2.75 | 445.45% | HC Wainwright & Co. | Raghuram Selvaraju | → $15 | Assumes | → Buy | Get Alert |
| 10/19/2021 | INDP | Buy Now | Indaptus Therapeutics | $2.75 | 481.82% | Maxim Group | Jason McCarthy | — | Upgrade | Hold → Buy | Get Alert |
FAQ
What is the target price for Indaptus Therapeutics (INDP)?
The latest price target for Indaptus Therapeutics (NASDAQ: INDP) was reported by HC Wainwright & Co. on April 15, 2024. The analyst firm set a price target for $12.00 expecting INDP to rise to within 12 months (a possible 336.36% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Indaptus Therapeutics (INDP)?
The latest analyst rating for Indaptus Therapeutics (NASDAQ: INDP) was provided by HC Wainwright & Co., and Indaptus Therapeutics reiterated their buy rating.
When was the last upgrade for Indaptus Therapeutics (INDP)?
The last upgrade for Indaptus Therapeutics Inc happened on October 19, 2021 when Maxim Group raised their price target to $16. Maxim Group previously had a hold for Indaptus Therapeutics Inc.
When was the last downgrade for Indaptus Therapeutics (INDP)?
There is no last downgrade for Indaptus Therapeutics.
When is the next analyst rating going to be posted or updated for Indaptus Therapeutics (INDP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Indaptus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Indaptus Therapeutics was filed on April 15, 2024 so you should expect the next rating to be made available sometime around April 15, 2025.
Is the Analyst Rating Indaptus Therapeutics (INDP) correct?
While ratings are subjective and will change, the latest Indaptus Therapeutics (INDP) rating was a reiterated with a price target of $0.00 to $12.00. The current price Indaptus Therapeutics (INDP) is trading at is $2.75, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.